SciBX: Science-Business eXchange Contents: April 4 2013, Volume 6 / Issue 13

TABLE OF CONTENTS April 4 2013, Volume 6 / Issue 13 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Hematology Infectious disease Musculoskeletal disease Neurology The Distillery: Techniques Computational models Drug platforms Imaging Markers Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The December 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a special feature on China's emerging biotech industry. This week, find out about how you can collaborate with Hong Kong Science & Technology Parks Corporation. Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer  Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.  SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Closer to class IIa HDAC inhibitors Tracey Baas doi:10.1038/scibx.2013.301 GlaxoSmithKline and its Tempero spinout have identified selective, first-in-class inhibitors of class IIa HDACs. The companies plan to study the trifluoromethyloxadiazole molecules in autoimmune disease. Full Text | PDF Targets and Mechanisms Top Glutamine metabolism drives PDAC Lauren Martz doi:10.1038/scibx.2013.302 Dana-Farber researchers have identified a glutamine metabolism pathway activated by oncogenic K-Ras in pancreatic cancers. The team found three different enzyme targets within the pathway that could be targeted to specifically inhibit tumor proliferation. Full Text | PDF Proteoglycans on the knee Tim Fulmer doi:10.1038/scibx.2013.303 Baylor College of Medicine researchers have shown that delivering the gene for proteoglycan 4 to the knee prevented and treated osteoarthritis in mice. GeneQuine has exclusively licensed the findings and is developing a gene therapy to treat OA in animals and patients. Full Text | PDF Tools Top The mechanical chemist Lev Osherovich doi:10.1038/scibx.2013.304 Cyclofluidic has shown that its automated microfluidic lead optimization platform can identify new BCR-ABL tyrosine kinase inhibitors. The company's next step is showing that automated hit-to-lead optimization will work with other targets and compound classes. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top IL-17; serum/glucocorticoid regulated kinase 1 (SGK1) doi:10.1038/scibx.2013.305 Two independent studies suggest inhibiting SGK1 could help treat autoimmune diseases. Full Text | PDF Cancer Top PHD finger protein 8 (PHF8) doi:10.1038/scibx.2013.306 In vitro and mouse studies suggest activating PHF8 could help restore sensitivity of APL to retinoic acid therapy. Full Text | PDF BRAF; KIAA1549 doi:10.1038/scibx.2013.307 Cell culture studies suggest second-generation BRAF inhibitors could help treat cancers that harbor the KIAA1549-BRAF fusion protein, which is found in low-grade astrocytomas. Full Text | PDF Chemokine CXC motif ligand 12 (CXCL12; SDF-1); CXC chemokine receptor 4 (CXCR4; NPY3R) doi:10.1038/scibx.2013.308 Mouse studies suggest an oncolytic virus encoding a CXCR4 antagonist could help treat and prevent breast cancer metastasis. Full Text | PDF Jumonji domain containing 1A (JMJD1A; TSGA) doi:10.1038/scibx.2013.309 Mouse and cell culture studies suggest inhibiting JMJD1A could help circumvent resistance to antiangiogenic cancer therapies. Full Text | PDF Glutamic-oxaloacetic transaminase 1 (GOT1); malate dehydrogenase 1 (MDH1); NADP-dependent malic enzyme (ME1) doi:10.1038/scibx.2013.310 In vitro and mouse studies suggest inhibiting cancer-specific glutamine metabolism could help treat K-Ras–mutant pancreatic cancers. Full Text | PDF Cardiovascular disease Top Epoxide hydrolase 2 (EPHX2; CEH) doi:10.1038/scibx.2013.311 Mouse studies suggest epoxide hydrolase inhibitors could be useful for preventing cardiac fibrosis. Full Text | PDF Hematology Top Not applicable doi:10.1038/scibx.2013.312 Mouse studies suggest disrupting the interaction between macrophages and erythroid cells could help treat conditions associated with disorders in erythropoiesis, such as β-thalassemia and polycythemia vera (PV). Full Text | PDF Infectious disease Top Plasmodium cytochrome bc1 doi:10.1038/scibx.2013.313 Mouse and cell culture studies suggest the 4(1H)-quinolone-3-diarylether ELQ-300 could help treat liver- and blood-stage malaria infections. Full Text | PDF Dipeptidyl peptidase-4 (DPP-4; CD26) doi:10.1038/scibx.2013.314 Cell culture studies identified DDP-4 as the receptor of human coronavirus–Erasmus Medical Center (hCoV-EMC) and suggest that blocking the protein could help treat infection. Full Text | PDF Musculoskeletal disease Top Not applicable doi:10.1038/scibx.2013.315 In vitro and mouse studies suggest depleting terminally differentiated CD8+ effector memory T cells could help prevent delayed fracture healing. Full Text | PDF Neurology Top Sorting nexin family member 27 (SNX27) doi:10.1038/scibx.2013.316 Patient sample and mouse studies suggest increasing SNX27 expression could help treat Down syndrome. Full Text | PDF Fragile X mental retardation 1 (FMR1); p21 protein (Cdc42 Rac)-activated kinase (PAK) doi:10.1038/scibx.2013.317 Mouse studies suggest the small molecule PAK inhibitor FRAX486 could help treat fragile X syndrome. Full Text | PDF Transient receptor potential A1 (TRPA1) doi:10.1038/scibx.2013.318 Mouse and cell culture studies suggest inhibiting TRPA1 could help prevent chemotherapy-induced sensory neuropathy. Full Text | PDF Distillery: Techniques Computational models Top Computational prediction of competitive endogenous RNA (ceRNA) effect on target expression doi:10.1038/scibx.2013.319 A computational model of ceRNA function could help identify new drug targets. Full Text | PDF Drug platforms Top Coagulation factor X (FX)-binding adenovirus 5 (Ad5) for systemic gene delivery doi:10.1038/scibx.2013.320 Cell culture and mouse studies suggest FX binding by Ad5 is required for efficient gene therapy with the vector. Full Text | PDF Crystal structures of serotonin (5-HT) receptor–bound agonists doi:10.1038/scibx.2013.321 Crystal structures of agonists bound to 5-HT receptors could aid the development of new compounds selective for 5-HT receptor subtypes. Full Text | PDF Structure/function analysis of multidrug and toxic compound extrusion (MATE)-family transporters to guide inhibitor development doi:10.1038/scibx.2013.322 Crystallographic analysis of a MATE-family transporter could guide the rational design of inhibitors that circumvent drug resistance mediated by the protein. Full Text | PDF Trifluoromethyloxadiazole (TFMO)-containing compounds to identify class IIa histone deacetylase (HDAC) inhibitors doi:10.1038/scibx.2013.323 TFMO-containing compounds could be used as research compounds to guide development of class IIa HDAC inhibitors. Full Text | PDF Imaging Top Sequence-specific labeling of multiple cell types in a sample using surface zinc fingers (sZFs) and fluorophore-tagged DNA probes doi:10.1038/scibx.2013.324 In vitro studies suggest a method using sZFs and fluorophore-tagged DNA probes could be useful for imaging multiple cell types in complex tissue samples. Full Text | PDF Markers Top Highly prevalent telomerase reverse transcriptase (TERT) promoter mutations in tumors including glioblastoma and bladder cancer doi:10.1038/scibx.2013.325 Highly prevalent mutations upstream of TERT could help guide the diagnosis and development of new treatments for various cancers. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.